This modality was successful at achieving complete angiographic exclusion of the aneurysm on the first attempt in 100% of patients. No major complications associated with the procedure were noted. This particular study concluded that endovascular therapy was effective and safe for splenic artery aneurysms and pseudoaneurysms. A newer study evaluated endovascular therapy for aneurysms and pseudoaneurysms of different visceral arteries including the splenic artery. In this study, immediate

exclusion of the aneurysm or pseudoaneurysm was achieved in 100% of patients, and all remained excluded on follow-up. There was one mortality from a new bleeding episode although this occurred in a patient with pseudoaneurysm of the celiac axis. selleck products Conclusion: Splenic artery pseudoaneurysms are rare and MI-503 are usually associated with chronic pancreatitis. They usually present with bleeding or abdominal pain. When found, immediate intervention is advocated whether by surgical or endovascular approaches, although recent studies have reported good efficacy and safety outcomes for endovascular therapies with lower mortality rates compared to surgery. No previous experience

with splenic artery pseudoaneurysms occurring in pregnancy were reported. This case illustrates that there may be a role for expectant management in such cases to allow better chances for survival of the fetus while maintaining preparedness to perform an intervention should complications arise. Key Word(s): 1. pseudoaneurysm; 2. splenic artery; 3. pregnancy; Presenting Author: MUZAFFAR GILL Additional Authors: UZMA GILL, HAFSA AZIZ, FARAH SALMAN, NEELUM ANWAR Corresponding Author: MUZAFFAR GILL Objective: Background:

Occult hepatitis MCE B infection (HepB surface antigen negative but HBV DNA positive) is considered more common in chronic hepatitis C infection patients than healthy subjects. Its clinical implications are not studied very well. We wanted to study the incidence and clinical significance of occult hepatitis B infection in chronic Hepatitis C patients Methods: Methods: From July 2009 to july 2010 we consecutively enrolled 100 chronic hepatitis C genotype 3 patients for treatment. They were HCVPCR positive and were cosideted eligible for treatment They were HbsAg negative. We tested them for HBV-DNA to rule out occult HBV infection. We did liver biopsy on this cohort to grade/stage the necroinflammation and fibrosis. They were labelled as group one. These patients were given Pegasys 180 ucg once weekly and 10 mg/kg Ribavirin daily for 6 months. In the same period we enrolled 100 healthy subjects who wanted to go for employment in gulf countries and had medical evaluation. They were negative for HCV antibody and HbsAg. We did HBV-PCR in this cohort to rule out occult HBV infection. This was labelled as group 2.